Objective To search the differenially expressed proteins in the serum of patients with unruptured intracranial aneurysm.Methods Eight patients with unruptured intracranial aneurysm,admitted to our hospital from July 2007 to September 2009,and 8 healthy adults(controls)were recruited in our study; two-dimensional differential in-gel electrophoresis(2D DIGE)and matrix-assisted laser desorption/ionization-time of flight mass spectrometry(MALDI-TOF-MS)were employed to analyze and identify the differentially expressed proteins in the serum of these patients and controls.Results As compared with the control group,patients with unruptured intracranial aneurysm had 29 differentially expressed proteins those enjoyed more than 1.5 folds differences; protein at spot 579was expressed as low as 1.81 folds in the serum of patients with unruptured intracranial aneurysm as compared with that in controls(P=0.008); the protein was identified as afamin using MALDI-TOF-MS.Conclusion The low expression of afamin in patients with unruptured intracranial aneurysm probably contributes to the formation and expansion of intracranial aneurysm.

Objective The aim of this study was to demonstrate the immunogenicity and safety of diphtheria, tetanus, pertussis (acellular, component) , poliomyelitis (inactivated) vaccine (adsorbed) and Haemophilus influenzae type b conjugate vaccine (DTaP-IPV//PRP-T) combined vaccine compared with commercially available DTaP (diphtheria, tetanus and pertussis), Haemophilus influenzae type b (Hib), tetanus conjugate and IPV monovalent vaccine. Methods Subjects were randomly divided into three groups, Group A and Group B were DTaP-IPV//PRP-T combined vaccine (PENTAXIMTM) vaccinated at 2,3,4 months of age or 3,4, 5 months of age respectively; Group C was commercially available DTaP. Hib tetanus conjugate (Act-HIBTM) and IPV (IMOVAX PolioTM) vaccines vaccinated at 3,4, 5 months of age. All groups received booster dose at 18 to 20 months of age, with antibody titers tested. Non-inferiority analysis was demonstrated in terms of seroprotection / seroconversion rates between Group A, Group B respectively and Group C. Safety information was collected after each vaccination to assess the safety of investigational vaccines. Results The non-inferiority of DTaP-IPV//PRP-T combined vaccine vaccinated at 2,3,4 or 3,4, 5 months of age versus DTaP, Hib tetanus conjugate and IPV vaccine was demonstrated for all vaccine antigens in both primary and booster phases in terms of seroprotection/seroconversion rates. DTaP-IPV//PRP-T combined vaccine was well tolerated. The rate of solicited/unsoliciated severe adverse reactions was very low and similar to the control vaccines. Conclusion DTaP-IPV//PRP-T combined vaccine was highly immunogenic with good safety profile in Chinese infants, which was comparable to the commercially available control vaccines.